This information was published on 2025-12-10T13:05:25 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2527919 (IR 1842201) |
| (220) |
25 Oct 2024
|
| (300) |
US, 01 May 2024, 98529313
|
| (511) (510) |
Class 5
Pharmaceuticals for the treatment of rare genetic diseases; pharmaceuticals for the treatment of musculo-skeletal disorders; pharmaceuticals for the treatment of skeletal dysplasia; pharmaceuticals for the treatment of cancer; pharmaceuticals for the treatment of cells that are resistant to drugs; pharmaceuticals for the treatment and prevention of drug resistance; anti-cancer pharmaceuticals. Class 44 Providing medical information; providing medical information in the field of rare diseases, musculo-skeletal disorders, and skeletal dysplasia; providing medical information via a website; providing information in the field of rare diseases, musculo-skeletal disorders, and skeletal dysplasia via a website; providing information in the field of the diagnosis and treatment of cancer via a website; providing medical information in the field of oncology; providing information in the field of the diagnosis and treatment of cancer via a website. |
| (540) | TYRA BIOSCIENCES |
| (550) | Word |
| (730) |
Tyra Biosciences, Inc.
|
| (750) |
Spruson & Ferguson
|
Find out more about publications on the About page.